Inactivation of MYC reverses tumorigenesis
Authors:
Open Access
- 19 March 2014
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 276 (1) , 52-60
Abstract
The MYC proto‐oncogene is an essential regulator of many normal biological programmes. MYC, when activated as an oncogene, has been implicated in the pathogenesis of most types of human cancers. MYC overexpression in normal cells is restrained from causing cancer through multiple genetically and epigenetically controlled checkpoint mechanisms, including proliferative arrest, apoptosis and cellular senescence. When pathologically activated in the correct epigenetic and genetic contexts, MYC bypasses these mechanisms and drives many of the ‘hallmark’ features of cancer, including uncontrolled tumour growth associated with DNA replication and transcription, cellular proliferation and growth, protein synthesis and altered cellular metabolism. MYC also dictates tumour cell fate by enforcing self‐renewal and by abrogating cellular senescence and differentiation programmes. Moreover, MYC influences the tumour microenvironment, including activating angiogenesis and suppressing the host immune response. Provocatively, brief or even partial suppression of MYC back to its physiological levels of activation can lead to the restoration of intrinsic checkpoint mechanisms, resulting in acute and sustained tumour regression associated with tumour cells undergoing proliferative arrest, differentiation, senescence and apoptosis, as well as remodelling of the tumour microenvironment, recruitment of an immune response and shutdown of angiogenesis. Hence, tumours appear to be addicted to the MYC oncogene because of both tumour cell intrinsic and host‐dependent mechanisms. MYC is important for the regulation of both the initiation and maintenance of tumorigenesis.Keywords
Funding Information
- National Institutes of Health (R01CA170378, U54CA149145, 5T32AI07290, 1F32CA177139, P50CA114747)
- Leukemia and Lymphoma Society (R6223-07)
- Burroughs Welcome Fund
This publication has 119 references indexed in Scilit:
- MYC on the Path to CancerCell, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Can Antitumor Immunity Help to Explain “Oncogene Addiction”?Cancer Cell, 2010
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene InactivationCancer Cell, 2010
- Evidence for a Growth-Stabilizing Regulatory Feedback Mechanism between Myc and Yorkie, the Drosophila Homolog of YapDevelopmental Cell, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Distinct Thresholds Govern Myc's Biological Output In VivoCancer Cell, 2008
- A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenesCancer Cell, 2006
- MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancerNature, 2004